FDA-approved1,2Evidence: Large human trialsHeart and blood vessels

Eptifibatide1

Also called Integrilin2

Key takeaway

Eptifibatide is a synthetic cyclic peptide that stops platelets from clumping together. It was first approved in the United States as Integrilin.1,2 Its U.S. label covers acute coronary syndrome (unstable angina or a heart attack without ST elevation) and patients undergoing percutaneous coronary intervention (PCI).1 In the PURSUIT trial of 10,948 people, death or a new heart attack within 30 days occurred in 14.2% with eptifibatide and 15.7% with placebo. The label warns that it can cause serious bleeding.1

Eptifibatide at a glance

What it isA cyclic heptapeptide that reversibly blocks the platelet glycoprotein IIb/IIIa receptor, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Integrilin with an original approval date of May 18, 1998. The cited label has no boxed warning.1,2
Human evidenceThree randomized, placebo-controlled trials (PURSUIT, IMPACT II and ESPRIT) in people with acute coronary syndromes or undergoing PCI, described in the label.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is eptifibatide?

Eptifibatide is a cyclic heptapeptide, a ring of six amino acids and one related residue closed by a disulfide bridge, made by chemical peptide synthesis, according to the label.1

Drugs@FDA lists the original application, Integrilin (NDA 020718), as discontinued; the label cited here is from another manufacturer.1,2

How does eptifibatide work?

The label states that eptifibatide reversibly inhibits platelet aggregation by preventing fibrinogen, von Willebrand factor and other molecules from binding the GP IIb/IIIa receptor on platelets.1

The inhibition reverses after the infusion stops, which is thought to result from eptifibatide detaching from platelets, according to the label.1

What do human studies show?

PURSUIT was a double-blind, randomized, placebo-controlled trial at 726 centers in 27 countries in 10,948 people with unstable angina or non-ST-elevation heart attack, according to the label.1

Death or new heart attack within 30 days occurred in 672 of 4,722 people (14.2%) on eptifibatide compared with 745 of 4,739 (15.7%) on placebo, a statistically significant difference, according to the label.1

The label also describes IMPACT II, in 4,010 people undergoing PCI, and ESPRIT, in people receiving coronary stents.1

What the evidence base contains

  • Large randomized human trial PURSUIT: a double-blind, randomized, placebo-controlled trial in 10,948 people with unstable angina or non-ST-elevation heart attack, described in the label.1
  • Large randomized human trial IMPACT II: a double-blind, randomized, placebo-controlled trial in 4,010 people undergoing PCI, described in the label.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is eptifibatide FDA-approved?

Yes. Drugs@FDA lists Integrilin, application NDA 020718, with an original approval date of May 18, 1998.2

The eptifibatide label cited here (DailyMed SPL version 13, published May 21, 2026) states that it is indicated to decrease death or new heart attack in acute coronary syndrome, and death, new heart attack or urgent intervention in patients undergoing PCI.1

The label has no boxed warning. It is contraindicated in people with recent abnormal bleeding, severe uncontrolled high blood pressure, recent major surgery or stroke, and its warnings state that it can cause serious bleeding.1

Timeline

  1. FDA approves Integrilin, according to Drugs@FDA.2
  2. DailyMed publishes the eptifibatide label version cited on this page.1

What is still unknown?

How its benefit compares in current practice: in PURSUIT, care followed each site’s usual standards, and most patients were managed without PCI during the infusion, according to the label.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Eptifibatide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Eptifibatide are a bounded selection, not every registration or paper about Eptifibatide. For the years before Eptifibatide was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Eptifibatide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Eptifibatide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Integrilin and generics for acute coronary syndrome and PCI. Randomized, placebo-controlled trials described in the label, including PURSUIT in 10,948 people, found fewer deaths or new heart attacks with eptifibatide. The label warns that it can cause serious bleeding.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Eptifibatide?

FDA-approved as Integrilin and generics for acute coronary syndrome and PCI. Randomized, placebo-controlled trials described in the label, including PURSUIT in 10,948 people, found fewer deaths or new heart attacks with eptifibatide. The label warns that it can cause serious bleeding.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
19
Drugs@FDA applications
15

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.↗Source date November 3, 2026
  2. Literature metadata · added November 15, 2026

    Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital.↗Source date October 10, 2026
  3. Literature metadata · added November 15, 2026

    The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.↗Source date May 18, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Eptifibatide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

65Selected dated records
67Connected citations
19Populated source years1997–2026
3/4Record lanes present

Registered human studies

Trial composition

16 of 16 selected trial records include at least one phase value; 16 of 16 include a status value in the retained structured contract.

PhasesPhase 2 9Phase 3 5Phase 4 2Phase 1 1
Status at observationCompleted 16

PubMed bibliography

Publication composition

30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 29Randomized Controlled Trial 9Comparative Study 8Multicenter Study 7Research Support, N.I.H., Extramural 4Research Support, Non-U.S. Gov't 4Case Reports 3Review 3Clinical Trial 2Clinical Trial, Phase I 1Clinical Trial, Phase II 1Clinical Trial, Phase III 1Comment 1Editorial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
15
FDA Federal Register documents
4
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
65

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 65 dated records

Research hub

Explore the Eptifibatide evidence record

Open all 65 records →
65Dated records
3Evidence types
65Cited public sources
19Source years

Change ledger

Recently changed for Eptifibatide

Open all 65 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00061373

PeptideScanner retained ClinicalTrials.gov record NCT00061373 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-02-04, and PeptideScanner's reviewed identity mapping was eptifibatide.

PeptideScanner change date
November 15, 2026
Cited source date
February 4, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00089895

PeptideScanner retained ClinicalTrials.gov record NCT00089895 at 2026-11-15T21:59:29.646Z. Its registry update date was 2024-05-17, and PeptideScanner's reviewed identity mapping was eptifibatide.

PeptideScanner change date
November 15, 2026
Cited source date
May 17, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00111566

PeptideScanner retained ClinicalTrials.gov record NCT00111566 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-11-28, and PeptideScanner's reviewed identity mapping was eptifibatide.

PeptideScanner change date
November 15, 2026
Cited source date
November 28, 2013
Evidence lane
Clinical trials

Official-source collections

Source records for Eptifibatide

Open the full research atlas →
PubMed30

30 with attributed title, venue, publication-date, and type metadata.

  1. Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital.Journal of research in pharmacy practice · 2026 02 24
  2. Prophylactic Intra-Arterial Eptifibatide in Stent-Assisted Coiling and Flow Diverter Treatment of Cerebral Aneurysms: A Single-Center Retrospective Analysis.Journal of clinical medicine · 2025 10 31
  3. Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.Neurology · 2025 10 10
Explore all selected literature →
ClinicalTrials.gov16

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT03735979Registry update February 7, 2025 · completed at observation
  2. NCT00089895Registry update May 17, 2024 · completed at observation
  3. NCT01522417Registry update May 13, 2021 · completed at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA15

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA213599Full FDA chronology · original submission status AP 2024-05-09
  2. ANDA213081Full FDA chronology · original submission status AP 2021-09-07
  3. ANDA207864Full FDA chronology · original submission status AP 2020-03-20
  4. ANDA204361Full FDA chronology · original submission status AP 2019-03-14
  5. ANDA204362Full FDA chronology · original submission status AP 2019-03-11
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Eptifibatide →

Evidence types

Coverage by source year

Selected records span December 17, 1997 to November 3, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 65

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.↗

    PubMed lists PMID 41071964 in Neurology as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, Comparative Study, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital.↗

    PubMed lists PMID 42846822 in Journal of research in pharmacy practice as Journal Article, with publication-date metadata of 2026-02-24 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.↗

    PubMed lists PMID 18772447 in Stroke as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2008-09-04 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.↗

    PubMed lists PMID 24534128 in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2014-02-15 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Eptifibatide in post-infarction angina patients who refused intervention: Ajmer postmyocardial infarction angina eptifibatide research (AJMER) study: a pilot study.↗

    PubMed lists PMID 25892271 in Cardiovascular therapeutics as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2015-08 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Prophylactic Intra-Arterial Eptifibatide in Stent-Assisted Coiling and Flow Diverter Treatment of Cerebral Aneurysms: A Single-Center Retrospective Analysis.↗

    PubMed lists PMID 41227129 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-10-31 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Unraveling the role of the homoarginine residue in antiplatelet drug eptifibatide in binding to the αIIbβ3 integrin receptor.↗

    PubMed lists PMID 35926348 in Thrombosis research as Journal Article, with publication-date metadata of 2022-07-25 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT03735979↗

    PeptideScanner retained ClinicalTrials.gov record NCT03735979 at 2026-11-15T21:59:29.646Z. Its registry update date was 2025-02-07, and PeptideScanner's reviewed identity mapping was eptifibatide.↗

  9. Literature metadata

    Eptifibatide use in ischemic stroke patients undergoing endovascular thrombectomy: A matched cohort analysis.↗

    PubMed lists PMID 36237613 in Frontiers in neurology as Journal Article, with publication-date metadata of 2022-09-27 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.↗

    PubMed lists PMID 23973010 in Thrombosis research as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-08-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT00089895↗

    PeptideScanner retained ClinicalTrials.gov record NCT00089895 at 2026-11-15T21:59:29.646Z. Its registry update date was 2024-05-17, and PeptideScanner's reviewed identity mapping was eptifibatide.↗

  12. Regulatory

    Drugs@FDA application ANDA213599↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213599 with status AP dated 2024-05-09, and names eptifibatide among the application record's active ingredients.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Eptifibatide injection (Baxter Healthcare Company) · SPL version 13 · published 2026-05-21 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: INTEGRILIN (eptifibatide), NDA 020718 · original approval May 18, 1998 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026